www.fdanews.com/articles/126740-collaboration-needed-to-develop-combination-cancer-therapies
Collaboration Needed to Develop Combination Cancer Therapies
May 4, 2010
More collaboration is needed if drugmakers
are to overcome the unique regulatory and financial hurdles of co-developing agents for combination cancer therapies, according to a recent Institute of
Medicine (IOM) report. When sponsors are reporting safety and efficacy trial data to the FDA, it can be difficult or impossible to measure and delineate
the contribution of each agent to the safety and efficacy of the product, the IOM says in the recently published report to the National Cancer Institute.
Clinical Trials Advisor
Clinical Trials Advisor